Published Academic Articles Medicinal Cannabis

Real-Life Experience With Purified Cannabidiol Treatment for Refractory Epilepsy: A Multicenter Retrospective Study

Purified CBD is well-tolerated and effective in reducing seizure frequency in children and young adults with DRE. Pediatric Neurology. Jan 2024

Medicinal Cannabis and Epilepsy

Potential Drug Interactions with Cannabinoids in Selected Chronic Diseases: Epilepsy, Autism Spectrum Disorders, Oncology, Multiple Sclerosis and Pain

This review critically summarizes the potential impact of cannabinoids in concomitance with other drugs in the following chronic diseases as Epilepsy, Autism Spectrum Disorders, Oncology, Multiple Sclerosis, and Chronic Pain Medicine and Pharmacology. Feb 2024

Medicinal Cannabis and Epilepsy

Multifaceted targets of cannabidiol in epilepsy: Modulating glutamate signaling and beyond

Computers in Biology and Medicine 2024

Medicinal Cannabis and Epilepsy

Decoding epilepsy treatment: A comparative evaluation contrasting cannabidiol pharmacokinetics in adult and paediatric populations

Chemico-Biological Interactions 2024

Medicinal Cannabis and Epilepsy

Efficacy and adverse event profile of cannabidiol and medicinal cannabis for treatment-resistant epilepsy: Systematic review and meta-analysis

Epilepsy & Behaviour 2020

Medicinal Cannabis and Epilepsy

Oral liquid cannabidiol (Epidyolex) for Dravet syndrome

NPS Medicinewise 2021

Medicinal Cannabis and Epilepsy

Cannabis-based products for pediatric epilepsy: A systematic review

Epilepsia 2019

Medicinal Cannabis and Epilepsy

Clinical Outcome Data of Children Treated with Cannabis-Based Medicinal Products for Treatment Resistant Epilepsy

Neuropediatrics, 2023

Medicinal Cannabis and Epilepsy

Efficacy and adverse event profile of cannabidiol and medicinal cannabis for treatment-resistant epilepsy: Systematic review and meta-analysis

CBD treatments were effective compared with placebo, regardless of the dose administered and there was a greater tendency for side-effects in short-term treatment compared with long-term treatment.

Medicinal Cannabis and Epilepsy

Food effect on pharmacokinetics of oral cannabidiol

Evaluates the pharmacokinetics of a purified oral cannabidiol (CBD) capsule administered with and without food in adults with refractory epilepsy. Epilepsia Sept 2019

Medicinal Cannabis and Epilepsy

Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence

Review evidence for cannabinoids as adjunctive treatments for treatment-resistant epilepsy. Journal of Neurology, Neurosurgery & Psychiatry 2018

Medicinal Cannabis and Epilepsy

Interaction between warfarin and cannabidiol, a case report

Medicinal Cannabis and Epilepsy

Cannabis based products for paediatric epilepsy

Evidence  suggests that cannabidiol probably reduces seizures among children with drug‐resistant epilepsy. At this time, the evidence is primarily limited to cannabidiol. Epilepsia July 2018

Medicinal Cannabis and Epilepsy

Knowledge, expectations and fears of cannabis use of epilepsy patients at a tertiary epilepsy center

Many patients are having to source information about medicinal cannabis from sources other than their doctor. In order to avoid prejudices and potentially harmful self-medication, doctors and healthcare providers are called to become familiar with the substance and to inform patients adequately. Epilepsy and Behaviour Aug 2019

Medicinal Cannabis and Epilepsy

Cannabis for epilepsy: is there enough evidence of efficacy?

With clinical trials of cannabidiol-based drugs under way, evidence for this treatment option may soon be forthcoming.

Medicinal Cannabis and Epilepsy

Cannabidiol reduces seizures and associated behavioral comorbidities in a range of animal seizure and epilepsy models

Patra PH, Barker-Haliski M, White HS, Whalley BJ, Glyn S, Sandhu H, Jones N, Bazelot M, Williams CM, McNeish AJ

Epilepsia Feb 2019 (Article)

Medicinal Cannabis and Epilepsy

Cannabis for refractory epilepsy in children: A review focusing on CDKL5 Deficiency Disorder

Dale T, Downs J, Olson H, Bergin AM, Smith S, Leonard H

Epilepsy Research Feb 2019 (Abstract)

Medicinal Cannabis and Epilepsy

Efficacy of cannabinoids in paediatric epilepsy

Ali S, Scheffer IE, Sadleir LG

Developmental Medicine & Child Neurology Jan 2019 (Abstract)

Medicinal Cannabis and Epilepsy

Therapeutic Use of medicinal cannabis in difficult to manage epilepsy

John A Lawson and Ingrid E Scheffer

British Journal of Clinical Pharmacology Nov 2018 (Article)

Medicinal Cannabis and Epilepsy

Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis

Lattanzi S, Brigo F, Trinka E, Zaccara G, Cagnetti C, Del Giovane C, Silvestrini M.

Drugs Nov 2018 (Abstract)

Medicinal Cannabis and Epilepsy

Real-Life Experience With Purified Cannabidiol Treatment for Refractory Epilepsy: A Multicenter Retrospective Study

Pediatric Neurology 2024

Medicinal Cannabis and Epilepsy Syndromes

Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial

Epilepsia 2022

Medicinal Cannabis and Epilepsy Syndromes

Long-term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open-label extension trial

Epilepsia 2021

Medicinal Cannabis and Epilepsy Syndromes

Long-Term Safety and Efficacy of Cannabidiol (CBD) Treatment in Patients with Dravet Syndrome

Long-term treatment with add-on CBD in patients with DS produced sustained seizure reductions, with no new safety concerns. Neurology April 2020

Medicinal Cannabis and Epilepsy Syndromes

A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome

Medicinal Cannabis and Epilepsy Syndromes

Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex

In this study, both cannabidiol dosages were equally efficacious in reducing tuberous sclerosis complex–associated seizures compared with placebo, but the smaller dosage led to fewer adverse events.

Medicinal Cannabis and Epilepsy Syndromes

Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes

The Annuals of Pharmacotherapy. 2019

Medicinal Cannabis and Epilepsy Syndromes

Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions

Epilepsia October 2019

Medicinal Cannabis and Epilepsy Syndromes

Cannabidiol in patients with Lennox‐Gastaut syndrome: Interim analysis of an open‐label extension study

Thiele E, Marsh E, Mazurkiewicz‐Beldzinska M, Halford JJ, Gunning B, Devinsky O, Checketts D, Roberts C

Epilepsia Mar 2019 (Article)

Medicinal Cannabis and Epilepsy Syndromes

Efficacy and Safety of Adjunctive Cannabidiol in Patients with Lennox-Gastaut Syndrome: A Systematic Review and Meta-Analysis

Lattanzi S, Brigo F, Cagnetti C, Trinka E and Silvestrini M

CNS Drugs Oct 2018 (Abstract)

Medicinal Cannabis and Epilepsy Syndromes

Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes

Devinsky O, Verducci C, Thiele EA, Laux LC, Patel AD, Filloux F, Szaflarski JP, Wilfong A, Clark GD, Park YD, Seltzer LE, Bebin EM, Flamini R, Wechsler RT and Friedman D

Epilepsy & Behavior Sep 2018 (Article)

Medicinal Cannabis and Epilepsy Syndromes

Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome

Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, Greenwood SM, Roberts C, Checketts D, Van Landingham KE and Zuberi SM

New England Journal of Medicine May 2018 (Abstract)

Medicinal Cannabis and Epilepsy Syndromes

Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome

Devinsky O, Patel AD, Thiele EA, Wong MH, Appleton R, Harden CL, Greenwood S, Morrison G and Sommerville K

Neurology Apr 2018 (Article)

Medicinal Cannabis and Epilepsy Syndromes

Cannabidiol as a Potential Treatment for Febrile Infection-Related Epilepsy Syndrome (FIRES) in the Acute and Chronic Phases

Gofshteyn JS, Wilfong A, Devinsky O, Bluvstein J, Charuta J, Ciliberto MA, Laux L, Marsh ED

Journal of Child Neurology Aug 2017 (Abstract)

Medicinal Cannabis and Epilepsy Syndromes

Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome

Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, Scheffer IE, Thiele EA and Wright S

New England Journal of Medicine May 2017 (Article)

Medicinal Cannabis and Epilepsy Syndromes

Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex

Hess EJ, Moody KA, Geffrey AL, Pollack SF, Skirvin LA, Bruno PL, Paolini JL and Thiele EA.

Epilepsia Oct 2016 (Article)

Medicinal Cannabis and Epilepsy Syndromes

Potential Drug Interactions with Cannabinoids in Selected Chronic Diseases: Epilepsy, Autism Spectrum Disorders, Oncology, Multiple Sclerosis and Pain

This review critically summarizes the potential impact of cannabinoids in concomitance with other drugs in the following chronic diseases as Epilepsy, Autism Spectrum Disorders, Oncology, Multiple Sclerosis, and Chronic Pain Medicine and Pharmacology. Feb 2024

Medicinal Cannabis Studies

Real-Life Experience With Purified Cannabidiol Treatment for Refractory Epilepsy: A Multicenter Retrospective Study

Pediatric Neurology 2024

Medicinal Cannabis Studies

Multifaceted targets of cannabidiol in epilepsy: Modulating glutamate signaling and beyond

Computers in Biology and Medicine 2024

Medicinal Cannabis Studies

Efficacy and safety of medical cannabinoids in children: a systematic review and meta-analysis

Scientific Reports, Dec 2021

Medicinal Cannabis Studies

Neuroprotective and Symptomatic Effects of Cannabidiol in an Animal Model of Parkinson’s Disease

International Journal of Molecular Science. August 2021

Medicinal Cannabis Studies

Overlapping patterns of recreational and medical cannabis use in a large community sample of cannabis users

Comprehensive Psychiatry

Volume 102, October 2020

Medicinal Cannabis Studies

Driving-Related Behaviours, Attitudes and Perceptions among Australian Medical Cannabis Users: Results from the CAMS 18-19 Survey

Accident Analysis & Prevention

Volume 148, December 2020

Medicinal Cannabis Studies

Medical cannabis use in the Australian community following introduction of legal access

Harm Reduction Journal (2020)

Medicinal Cannabis Studies

The safety, tolerability and pharmacokinetics of a cannabidiol administered as single-dose oil solution and single and multiple doses of a sublingual wafer in healthy volunteers. Phase 1 trial.

No serious adverse events reported. The most common related adverse side effects were sleepiness, sedation and altered mood, and these were all mild or moderate in severity. BJCP-MediCabilis Phase I study

Medicinal Cannabis Studies

Practical considerations in medical cannabis administration and dosing

European Journal of Internal Medicine. March 2018

Medicinal Cannabis Studies

Update of cannabis and its medical use

WHO 2015

Medicinal Cannabis Studies

Medical Cannabis: Adverse Effects and Drug Interactions

Medicinal Cannabis Studies

Real life Experience of Medical Cannabis Treatment in Autism: Analysis of Safety and Efficacy

www.nature.com 2019

Medicinal Cannabis Studies

Review of the neurological benefits of phytocannabinoids

Surgical Neurology International

Medicinal Cannabis Studies

Patient-reported use of medical cannabis for pain, anxiety, and depression symptoms

Social Science & Medicine 2019

Medicinal Cannabis Studies

Medical Cannabis for Neuropathic Pain

Current Pain and Headache Reports 2018

Medicinal Cannabis Studies

Cannabinoids in Glioblastoma Therapy: New Applications for Old Drugs

Medicinal Cannabis Studies

Benefits and harms of medicinal cannabis

Medicinal Cannabis Studies

Association between medical cannabis laws and opioid overdose mortality has reversed over time

Medical cannabis has been touted as a solution to the US opioid overdose crisis since studies found that from 1999 to 2010 states with medical cannabis laws experienced slower increases in opioid overdose mortality.

Medicinal Cannabis Studies

Treatment of Tourette Syndrome with Cannabis-Based Medicine:

Cannabis based medicine might be effective and safe in the treatment of tics and comorbidities at least in a subgroup of adult patients with Tourette’s Syndrome

Medicinal Cannabis Studies

Oral liquid cannabidiol (Epidyolex) for Dravet syndrome

NPS Medicinewise 2021

Medicinal Cannabis in Australia

Medicinal Cannabis Guidance and Resources for Health Professionals to Inform Clinical Decision Making

Clinical Therapeutics, Jun 2023

Medicinal Cannabis in Australia

Driving-Related Behaviours, Attitudes and Perceptions among Australian Medical Cannabis Users: Results from the CAMS 18-19 Survey

Accident Analysis & Prevention

Volume 148, December 2020

Medicinal Cannabis in Australia

Epidyolex Consumer Medical Information (Australia)

Medicinal Cannabis in Australia

Medical Cannabis: What you need to know

Information and resources for consumers and health professionals.

NPS Medicinewise 2020

Medicinal Cannabis in Australia

Patient-reported use of medical cannabis for pain, anxiety, and depression symptoms

Social Science & Medicine 2019

Medicinal Cannabis in Australia

Medical Cannabis: What’s the Evidence?

Interview with Dr Norman Swan

Medicinal Cannabis in Australia

Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions

Epilepsia October 2019

Medicinal Cannabis in Australia

Survey of Australian psychiatrists’ and psychiatry trainees’ knowledge about and attitudes towards medicinal cannabinoids

Jacobs NI, Montebello M, Monds LA, Lintzeris N

Australasian Psychiatry Feb 2019 (Abstract)

Medicinal Cannabis in Australia

Medicinal cannabis in Australia,2016 : the Cannabis as Medicine Survey (CAMS-16)

Nicholas Lintzeris, Jessica Driels, Natalie Elias, Jonathon C Arnold, Iain S McGregor and David J Allsop

Medical Journal of Australia Sep 2018 (Article)

Medicinal Cannabis in Australia

Medicinal Cannabis and the Tyranny of Distance: Policy Reform Required for Optimizing Patient and Health System Net Benefit in Australia

David Caldicott, Justin Sinclair, Lynnaire Sheridan and Simon Eckermann

Applied Health Economics and Health Policy Apr 2018 (Article)

Medicinal Cannabis in Australia